Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data

View Full Paper
Ask AI
Bookmark
Share

Authors

HEHany ElmariahLMLori MufflyMNMariam T. Nawas

Discussion

Loading...

Member takes

Overview

Analysis reveals graft-versus-host disease outcomes improve with fludarabine/melphalan in older AML/MDS patients undergoing allogeneic stem cell transplantation.

Key Points

  • To evaluate the efficacy of fludarabine-based reduced intensity regimens in older AML/MDS patients undergoing allogeneic stem cell transplantation.
  • Included patients aged ≥50 years from CIBMTR registry between 2013 and 2022.
  • Analyzed outcomes of five fludarabine-based conditioning regimens for patients undergoing alloHCT.
  • Used propensity score inverse probability weighting to minimize treatment allocation bias.
  • FM100 and FM140 regimens associated with higher overall survival compared to other regimens.
  • Significantly lower relapse rates observed in FM100 and FM140 under multivariable analysis.
  • Higher early transplant-related mortality noted with FM regimens but improved long-term outcomes observed.

Cite This Study

Elmariah et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cffdhttps://doi.org/10.1182/blood-2025-109
View Full Paper
Ask AI
Bookmark
Share